Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01DA030234 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Drug Abuse (NIDA) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The relevance of this research to public health is to make it possible to test for hepatitis C and syphilis at point of care so that people will receive their results immediately instead of requiring people to wait for at least a week to get their test results. This research will make rapid tests for HIV available that can detect HIV infection earlier and are more accurate than current tests available in the United States.
This application addresses "Studies to improve access and utilization of HIV counseling and testing" for "HIV/AIDS and AIDS-related co-infections" such as "hepatitis C virus (HCV), other sexually transmitted infections (STIs)" that are part of PA-07-307 Drug Abuse Aspects of HIV/AIDS. The only rapid tests that are approved for use in the US currently are for HIV infection. Tests for other conditions such as hepatitis C (HCV) and syphilis are in use in other countries. In response to an Opportunity that the CDC published in the Federal Register, there are now candidate rapid test kits for HCV and syphilis available for experimental use in the US. Different combinations of rapid and standard tests will be offered to participants in a four-arm trial to assess which tests are accepted by the participants. Only a minority of clients at CBRS who have been offered the rapid test for HIV have accepted it. Those who chose rapid HIV tests were more likely to be male, educated, gay, young and White. They were less likely to be Black, or injection drug users. The proposed study has the potential to have a significant impact upon screening for HIV, syphilis, and HCV. Rapid tests have the potential to increase the receipt of test results, particularly among groups that are less likely to return for their results using traditional testing. The candidate tests are designed for Point of Care (either oral fluid and/or whole blood), and thus will require real-time testing, so the trial will be able to evaluate both the accuracy of the tests in settings of intended use and their acceptability to potential clients in real-world situations.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| All tests. | Experimental | Choose from all 16 possible tests. |
|
| HIV/HCV | Active Comparator | Choice of 10 different HIV and hepatitis C tests in the bundle. |
|
| HIV/Syphilis | Active Comparator | Choice of 7 different tests for HIV and syphilis. |
|
| HIV only | Active Comparator | Choice of 4 rapid tests for HIV only. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Rapid tests for HIV, HCV, HBV, and syphilis | Device | Choice of 16 different rapid tests. Only 12 manufacturer and names are shown because some are used with both blood and oral fluid. When they are used on both specimens, they are counted as two tests. |
| Measure | Description | Time Frame |
|---|---|---|
| Test choice profile | Which tests do participants choose to receive when bundled in different combinations? | one day (day one of study) |
| Measure | Description | Time Frame |
|---|---|---|
| Return for standard test results | Is there a different return for test results rate for the different arms of the study? | one week |
Not provided
Inclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Dennis G Fisher, Ph.D. | California State University, Long Beach | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Center for Behavioral Research and Services | Long Beach | California | 90813 | United States |
| Type | Date | Date Unknown |
|---|---|---|
| Release | Feb 25, 2016 | |
| Reset | Mar 24, 2016 | |
| Release | Jul 25, 2018 | |
| Reset | Aug 21, 2018 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Feb 25, 2016 | Mar 24, 2016 | |||
| Jul 25, 2018 |
| ID | Term |
|---|---|
| D006526 | Hepatitis C |
| D006509 | Hepatitis B |
| D013587 | Syphilis |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D006525 | Hepatitis, Viral, Human |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| HIV/HCV | Device | Choice of 10 different tests for HIV and hepatitis C. |
|
|
| HIV/syphilis | Device | Choice of 7 different tests for HIV and syphilis |
|
|
| HIV only | Device | Choice of 4 different tests for HIV only. |
|
|
| Aug 21, 2018 |
| D014777 |
| Virus Diseases |
| D018178 | Flaviviridae Infections |
| D012327 | RNA Virus Infections |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D018347 | Hepadnaviridae Infections |
| D004266 | DNA Virus Infections |
| D014211 | Treponemal Infections |
| D013145 | Spirochaetales Infections |
| D016905 | Gram-Negative Bacterial Infections |
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
| D015231 | Sexually Transmitted Diseases, Bacterial |
| D012749 | Sexually Transmitted Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |